LAVA Therapeutics (NASDAQ:LVTX) Sees Significant Increase in Short Interest

LAVA Therapeutics (NASDAQ:LVTX) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 58,700 shares, an increase of 178.2% from the November 30th total of 21,100 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 89,100 shares, the short-interest ratio is presently 0.7 days.

Institutional Trading of LAVA Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LVTX. XTX Topco Ltd bought a new stake in shares of LAVA Therapeutics during the second quarter valued at approximately $55,000. Virtu Financial LLC acquired a new position in LAVA Therapeutics during the 3rd quarter worth $32,000. Finally, Pathway Financial Advisors LLC boosted its position in LAVA Therapeutics by 70.8% in the 3rd quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after buying an additional 42,500 shares during the last quarter.

Analyst Ratings Changes

LVTX has been the topic of several recent analyst reports. Leerink Partnrs downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. HC Wainwright decreased their target price on LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, December 20th. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Finally, Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.33.

LAVA Therapeutics Trading Up 0.1 %

NASDAQ LVTX traded up $0.00 during trading hours on Friday, reaching $0.99. 253,037 shares of the company’s stock were exchanged, compared to its average volume of 515,669. The firm has a fifty day moving average of $1.56 and a 200-day moving average of $1.73. LAVA Therapeutics has a one year low of $0.88 and a one year high of $6.47. The stock has a market cap of $25.18 million, a PE ratio of -0.96 and a beta of 0.43.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.